Siemens Fonds Invest GmbH Grows Position in Henry Schein, Inc. (NASDAQ:HSIC)

Siemens Fonds Invest GmbH grew its stake in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 282.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,366 shares of the company's stock after acquiring an additional 9,870 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Henry Schein were worth $925,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its holdings in Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company's stock worth $52,000 after acquiring an additional 143 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of Henry Schein by 2.5% in the fourth quarter. Guggenheim Capital LLC now owns 6,428 shares of the company's stock worth $445,000 after purchasing an additional 159 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Henry Schein by 1.0% in the fourth quarter. CIBC Asset Management Inc now owns 17,849 shares of the company's stock worth $1,235,000 after purchasing an additional 169 shares during the last quarter. Metis Global Partners LLC raised its stake in shares of Henry Schein by 4.7% in the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company's stock worth $291,000 after purchasing an additional 187 shares during the last quarter. Finally, Sanctuary Advisors LLC raised its stake in shares of Henry Schein by 5.0% in the fourth quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company's stock worth $294,000 after purchasing an additional 203 shares during the last quarter. 96.62% of the stock is owned by institutional investors.

Henry Schein Stock Performance

HSIC traded down $2.12 during midday trading on Friday, reaching $69.86. The company had a trading volume of 3,123,095 shares, compared to its average volume of 1,672,150. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average of $67.65 and a two-hundred day moving average of $71.66. The company has a market cap of $8.50 billion, a P/E ratio of 28.75, a P/E/G ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49.

Henry Schein (NASDAQ:HSIC - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.11 by $0.04. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business's quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.10 earnings per share. As a group, equities research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the sale, the director now owns 24,805 shares in the company, valued at approximately $1,762,147.20. This trade represents a 9.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the sale, the chief executive officer now owns 62,688 shares of the company's stock, valued at $4,460,251.20. This represents a 6.05% decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company's stock.

Wall Street Analyst Weigh In

HSIC has been the subject of several recent analyst reports. Piper Sandler decreased their price target on Henry Schein from $83.00 to $77.00 and set an "overweight" rating for the company in a research note on Wednesday, April 30th. Wall Street Zen cut Henry Schein from a "buy" rating to a "hold" rating in a research note on Thursday, April 17th. Barrington Research decreased their price target on Henry Schein from $90.00 to $86.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Wells Fargo & Company decreased their price target on Henry Schein from $80.00 to $75.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, UBS Group reduced their price objective on Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research report on Wednesday, February 26th. Six equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $79.30.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.